Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma.

Becker PS.

J Clin Oncol. 2011 Mar 1;29(7):783-6. doi: 10.1200/JCO.2010.33.4771. Epub 2011 Jan 18. No abstract available.

2.

Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.

Jo JC, Kang BW, Sym SJ, Lee SS, Jang G, Kim S, Lee DH, Kim SW, Lee JS, Suh C.

Invest New Drugs. 2011 Feb;29(1):175-81. doi: 10.1007/s10637-009-9343-4. Epub 2009 Oct 13.

PMID:
19823768
3.

Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.

Richardson PG.

Lancet Oncol. 2010 Nov;11(11):1014-6. doi: 10.1016/S1470-2045(10)70248-5. No abstract available.

PMID:
21051016
4.

[Adverse effects of PAD and VAD regimens in multiple myeloma patients].

Zhao Y, Jing Y, Bo J, Li HH, Wang SH, Huang WR, Zhu HY, Han XP, Dou LP, Wang FF, Li F, Gao CJ, Wang QS, Yu L.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Aug;18(4):1027-30. Chinese.

PMID:
20723322
5.

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BG, Van Ness B, Child JA, Sonneveld P, Morgan GJ.

J Clin Oncol. 2011 Mar 1;29(7):797-804. doi: 10.1200/JCO.2010.28.0792. Epub 2011 Jan 18.

6.

VBAMDex chemotherapy in advanced multiple myeloma.

Peest D, Schmoll HJ, Schedel I, Gl├╝ck S, Schumacher K, Deicher H.

Eur J Haematol. 1988 Mar;40(3):245-9.

PMID:
3356240
7.
8.

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

Barlogie B, Smith L, Alexanian R.

N Engl J Med. 1984 May 24;310(21):1353-6.

PMID:
6546971
9.
10.

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch, Panagiotidis P, Korantzis J, Tzilianos M, Maniatis A; Greek Myeloma Study Group.

Ann Oncol. 2004 Jan;15(1):134-8.

11.

VAD-based regimens as primary treatment for multiple myeloma.

Alexanian R, Barlogie B, Tucker S.

Am J Hematol. 1990 Feb;33(2):86-9.

PMID:
2301376
12.

Bilateral transient hearing loss associated with vincristine therapy: case report.

Aydogdu I, Ozturan O, Kuku I, Kaya E, Sevinc A, Yildiz R.

J Chemother. 2000 Dec;12(6):530-2.

PMID:
11154039
13.

[Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].

Sarkisova IA, Rameev VV, Kozlovskaia LV, Andreeva NE.

Ter Arkh. 2003;75(8):81-2. Russian. No abstract available.

PMID:
14520860
14.

Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine.

Escuro RS, Adelstein DJ, Carter SG.

Cleve Clin J Med. 1992 Nov-Dec;59(6):643-4.

PMID:
1424076
15.

Amyloid deposition of systemic myeloma-associated amyloidosis excludes actinic elastotic material.

Wada N, Fujimoto N, Komatsu T, Tajima S, Ishibashi A.

Eur J Dermatol. 2002 Nov-Dec;12(6):607-8.

PMID:
12459542
16.

VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion?

Koskela K, Pelliniemi TT, Remes K.

Leuk Lymphoma. 1993 Jul;10(4-5):347-51.

PMID:
8220133
17.
18.

Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.

Chou T, Tobinai K, Uike N, Asakawa T, Saito I, Fukuda H, Mizoroki F, Ando K, Iida S, Ueda R, Tsukasaki K, Hotta T; Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG), Japan.

Jpn J Clin Oncol. 2011 Apr;41(4):586-9. doi: 10.1093/jjco/hyq245. Epub 2011 Jan 19.

19.

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P.

J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.

20.
Items per page

Supplemental Content

Write to the Help Desk